See the more-recent, 2019 NASH Report
InCrowd conducted 30-minute MicroQual interviews with four physicians considered key opinion leaders on Non-alcoholic Steatohepatitis (NASH). Then used this feedback to develop a 5-minute quantitative MicroSurvey for 55 gastroentologists and hepatologists.
Research Objectives:
-
Determine physician interests in and perspectives on NASH treatments in development.
-
Gauge the prevalence of comorbid conditions that require physician management alongside NASH and understand which physician specialties are ultimately stakeholders in patient care.
Methodology:
Method: 5-minute MicroSurvey via InCrowd
Crowds: US Gastroenterologists, Hepatologists
Sample Size: n=55
Fielding Period: April 25-26, 2018
One key insight: physicians feel that any effective treatment for NASH will need to be a combination regimen, versus a single agent, that helps resolve liver fibrosis, reduce liver inflammation, and interrupt the storage of fat in the liver.
Download the full report now!
